6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hahn J.-Y. | - |
dc.contributor.author | Song Y.B. | - |
dc.contributor.author | Oh J.-H. | - |
dc.contributor.author | Cho D.-K. | - |
dc.contributor.author | Lee J.B. | - |
dc.contributor.author | Doh J.-H. | - |
dc.contributor.author | Kim S.-H. | - |
dc.contributor.author | Jeong J.-O. | - |
dc.contributor.author | Bae J.-H. | - |
dc.contributor.author | Kim B.-O. | - |
dc.contributor.author | Cho J.H. | - |
dc.contributor.author | Suh I.-W. | - |
dc.contributor.author | Kim D.-I. | - |
dc.contributor.author | Park H.-K. | - |
dc.contributor.author | Park J.-S. | - |
dc.contributor.author | Choi W.G. | - |
dc.contributor.author | Lee W.S. | - |
dc.contributor.author | Kim J. | - |
dc.contributor.author | Choi K.H. | - |
dc.contributor.author | Park T.K. | - |
dc.contributor.author | Lee J.M. | - |
dc.contributor.author | Yang J.H. | - |
dc.contributor.author | Choi J.-H. | - |
dc.contributor.author | Choi S.-H. | - |
dc.contributor.author | Gwon H.-C. | - |
dc.contributor.author | Gwon H.-C. | - |
dc.contributor.author | Hahn J.-Y. | - |
dc.contributor.author | Song Y.B. | - |
dc.contributor.author | Park T.K. | - |
dc.contributor.author | Lee J.M. | - |
dc.contributor.author | Yang J.H. | - |
dc.contributor.author | Choi J.-H. | - |
dc.contributor.author | Choi S.-H. | - |
dc.contributor.author | Lee J.-Y. | - |
dc.contributor.author | Choi W.G. | - |
dc.contributor.author | Bae J.-H. | - |
dc.contributor.author | Park H.S. | - |
dc.contributor.author | Hwang J.-Y. | - |
dc.contributor.author | Hur S.-H. | - |
dc.contributor.author | Rha S.-W. | - |
dc.contributor.author | Cho D.-K. | - |
dc.contributor.author | Cho S.C. | - |
dc.contributor.author | Kang W.Y. | - |
dc.contributor.author | Lim S.-H. | - |
dc.contributor.author | Lee J.B. | - |
dc.contributor.author | Kim M.H. | - |
dc.contributor.author | Cha K.S. | - |
dc.contributor.author | Choi R.K. | - |
dc.contributor.author | Chae I.-H. | - |
dc.contributor.author | Oh J.-H. | - |
dc.contributor.author | Jang W.J. | - |
dc.contributor.author | Park Y.H. | - |
dc.contributor.author | Chun W.J. | - |
dc.contributor.author | Kim S.-H. | - |
dc.contributor.author | Cho J.H. | - |
dc.contributor.author | Suh I.-W. | - |
dc.contributor.author | Park J.-S. | - |
dc.contributor.author | Choi J.W. | - |
dc.contributor.author | Kim B.-O. | - |
dc.contributor.author | Doh J.-H. | - |
dc.contributor.author | Kim D.-I. | - |
dc.contributor.author | Jeong M.H. | - |
dc.contributor.author | Kang S.H. | - |
dc.contributor.author | Lee W.S. | - |
dc.contributor.author | Park H.-K. | - |
dc.contributor.author | Jeong J.-O. | - |
dc.contributor.author | Ahn K.-J. | - |
dc.contributor.author | SMART-DATE investigators | - |
dc.date.available | 2020-11-10T08:52:10Z | - |
dc.date.issued | 2018-03 | - |
dc.identifier.issn | 0140-6736 | - |
dc.identifier.issn | 1474-547X | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/29254 | - |
dc.description.abstract | Background: Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in patients with acute coronary syndrome. However, available data about the optimal duration of DAPT in patients with acute coronary syndrome undergoing percutaneous coronary intervention are scant. We aimed to investigate whether a 6-month duration of DAPT would be non-inferior to the conventional 12-month or longer duration of DAPT in this population. Methods: We did a randomised, open-label, non-inferiority trial at 31 centres in South Korea. Patients were eligible if they had unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction, and underwent percutaneous coronary intervention. Enrolled patients were randomly assigned, via a web-based system by computer-generated block randomisation, to either the 6-month DAPT group or to the 12-month or longer DAPT group, with stratification by site, clinical presentation, and diabetes. Assessors were masked to treatment allocation. The primary endpoint was a composite of all-cause death, myocardial infarction, or stroke at 18 months after the index procedure in the intention-to-treat population. Secondary endpoints were the individual components of the primary endpoint; definite or probable stent thrombosis as defined by the Academic Research Consortium; and Bleeding Academic Research Consortium (BARC) type 2–5 bleeding at 18 months after the index procedure. The primary endpoint was also analysed per protocol. This trial is registered with ClinicalTrials.gov, number NCT01701453. Findings: Between Sept 5, 2012, and Dec 31, 2015, we randomly assigned 2712 patients; 1357 to the 6-month DAPT group and 1355 to the 12-month or longer DAPT group. Clopidogrel was used as a P2Y12 inhibitor for DAPT in 1082 (79·7%) patients in the 6-month DAPT group and in 1109 (81·8%) patients in the 12-month or longer DAPT group. The primary endpoint occurred in 63 patients in the 6-month DAPT group and in 56 patients in the 12-month or longer DAPT group (cumulative event rate 4·7% vs 4·2%; absolute risk difference 0·5%; upper limit of one-sided 95% CI 1·8%; pnon-inferiority=0·03 with a predefined non-inferiority margin of 2·0%). Although all-cause mortality did not differ significantly between the 6-month DAPT group and the 12-month or longer DAPT group (35 [2·6%] patients vs 39 [2·9%]; hazard ratio [HR] 0·90 [95% CI 0·57–1·42]; p=0·90) and neither did stroke (11 [0·8%] patients vs 12 [0·9%]; 0·92 [0·41–2·08]; p=0·84), myocardial infarction occurred more frequently in the 6-month DAPT group than in the 12-month or longer DAPT group (24 [1·8%] patients vs ten [0·8%]; 2·41 [1·15–5·05]; p=0·02). 15 (1·1%) patients had stent thrombosis in the 6-month DAPT group compared with ten (0·7%) in the 12-month or longer DAPT group (HR 1·50 [95% CI 0·68–3·35]; p=0·32). The rate of BARC type 2–5 bleeding was 2·7% (35 patients) in the 6-month DAPT group and 3·9% (51 patients) in the 12-month or longer DAPT group (HR 0·69 [95% CI 0·45–1·05]; p=0·09). Results from the per-protocol analysis were similar to those from the intention-to-treat analysis. Interpretation: The increased risk of myocardial infarction with 6-month DAPT and the wide non-inferiority margin prevent us from concluding that short-term DAPT is safe in patients with acute coronary syndrome undergoing percutaneous coronary intervention with current-generation DES. Prolonged DAPT in patients with acute coronary syndrome without excessive risk of bleeding should remain the standard of care. Funding: Abbott Vascular Korea, Medtronic Vascular Korea, Biosensors Inc, and Dong-A ST. © 2018 Elsevier Ltd | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Lancet Publishing Group | - |
dc.title | 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/S0140-6736(18)30493-8 | - |
dc.identifier.scopusid | 2-s2.0-85043381536 | - |
dc.identifier.wosid | 000428791600026 | - |
dc.identifier.bibliographicCitation | The Lancet, v.391, no.10127, pp 1274 - 1284 | - |
dc.citation.title | The Lancet | - |
dc.citation.volume | 391 | - |
dc.citation.number | 10127 | - |
dc.citation.startPage | 1274 | - |
dc.citation.endPage | 1284 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | acetylsalicylic acid | - |
dc.subject.keywordPlus | clopidogrel | - |
dc.subject.keywordPlus | prasugrel | - |
dc.subject.keywordPlus | ticagrelor | - |
dc.subject.keywordPlus | acetylsalicylic acid | - |
dc.subject.keywordPlus | antithrombocytic agent | - |
dc.subject.keywordPlus | clopidogrel | - |
dc.subject.keywordPlus | ticlopidine | - |
dc.subject.keywordPlus | acute coronary syndrome | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | all cause mortality | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | cerebrovascular accident | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | dual antiplatelet therapy | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | heart infarction | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | intention to treat analysis | - |
dc.subject.keywordPlus | loading drug dose | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | multicenter study | - |
dc.subject.keywordPlus | non ST segment elevation myocardial infarction | - |
dc.subject.keywordPlus | non-inferiority trial | - |
dc.subject.keywordPlus | open study | - |
dc.subject.keywordPlus | percutaneous coronary intervention | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | prospective study | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | South Korea | - |
dc.subject.keywordPlus | ST segment elevation myocardial infarction | - |
dc.subject.keywordPlus | stent thrombosis | - |
dc.subject.keywordPlus | treatment duration | - |
dc.subject.keywordPlus | unstable angina pectoris | - |
dc.subject.keywordPlus | acute coronary syndrome | - |
dc.subject.keywordPlus | analogs and derivatives | - |
dc.subject.keywordPlus | clinical trial | - |
dc.subject.keywordPlus | combination drug therapy | - |
dc.subject.keywordPlus | comparative study | - |
dc.subject.keywordPlus | drug administration | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | Acute Coronary Syndrome | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Aspirin | - |
dc.subject.keywordPlus | Drug Administration Schedule | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Percutaneous Coronary Intervention | - |
dc.subject.keywordPlus | Platelet Aggregation Inhibitors | - |
dc.subject.keywordPlus | Prospective Studies | - |
dc.subject.keywordPlus | Republic of Korea | - |
dc.subject.keywordPlus | Ticlopidine | - |
dc.subject.keywordPlus | Treatment Outcome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.